PE20021158A1 - Derivados de sulfonamida como antagonistas del receptor de bradiquinina - Google Patents
Derivados de sulfonamida como antagonistas del receptor de bradiquininaInfo
- Publication number
- PE20021158A1 PE20021158A1 PE2002000401A PE2002000401A PE20021158A1 PE 20021158 A1 PE20021158 A1 PE 20021158A1 PE 2002000401 A PE2002000401 A PE 2002000401A PE 2002000401 A PE2002000401 A PE 2002000401A PE 20021158 A1 PE20021158 A1 PE 20021158A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- ilo
- bradiquinin
- indan
- sulfonamide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A DERIVADOS DE SULFONAMIDA DE FORMULA I DONDE R1 ES FENILO, 1,2-DICLOROFENILO, 3-METILFENILO, 3-BROMOFENILO, NAFT-2-ILO, INDAN-5-ILO, BENZO[1,3]DIOXOL-5-ILO, 1,2,3,4-TETRAHIDRONAFT-6-ILO; R2 ES H, HALOGENO, ALQUILO C1-C4; R3 ES H, HALOGENO, ALQUILO C1-C4; R4 Y R5 SON H, ALQUILO C1-C4; R6 ES CH2OH, TETRAZOL-5-ILO, 1,2,4-TRIAZOL-5-ILO, 1,2,3-TRIAZOL-5-ILO, COOH, CONH2, ZNH(CH2)nCHR7R8; Z ES CO, CH2; n ES 0-4; R7 ES ALQUILO C1-C4, COOH, COO-ALQUILO C1-C4; R8 ES H, ALQUILO C1-C4, ARILO C5-C10, HETEROARILO C5-C10, ALQUILO C1-C4-ARILO C5-C10, ALQUILO C1-C4-HETEROARILO C5-C10; TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION Y COMPUESTOS INTERMEDIOS. SON COMPUESTOS PREFERIDOS (S)-3-(2-{(4-BROMO-2-CLORO-BENCENOSULFONIL)-[2-(INDAN-5-ILOXI)-ETIL]-AMINO}-ACETILAMINO)-4-FENILBUTIRICO; 2,4-DICLORO-N-[2-(INDAN-5-ILOXI)-ETIL]-N-(1H-TETRAZOL-5-ILMETIL)BENCENOSULFONAMIDA. LOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE BRADIQUININA B1 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DEL DOLOR, HIPERALGESIA, INFLAMACION, EDEMA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29082701P | 2001-05-14 | 2001-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20021158A1 true PE20021158A1 (es) | 2003-03-03 |
Family
ID=23117717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002000401A PE20021158A1 (es) | 2001-05-14 | 2002-05-14 | Derivados de sulfonamida como antagonistas del receptor de bradiquinina |
Country Status (13)
Country | Link |
---|---|
US (1) | US7109203B2 (es) |
EP (1) | EP1389183B1 (es) |
JP (1) | JP4150597B2 (es) |
CN (1) | CN1268610C (es) |
AR (1) | AR035891A1 (es) |
AT (1) | ATE459598T1 (es) |
BR (1) | BR0209386A (es) |
CA (1) | CA2443721A1 (es) |
DE (1) | DE60235536D1 (es) |
ES (1) | ES2340664T3 (es) |
PE (1) | PE20021158A1 (es) |
PT (1) | PT1389183E (es) |
WO (1) | WO2002092556A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
WO2001062979A2 (en) | 2000-02-23 | 2001-08-30 | Cv Therapeutics, Inc. | Dentification of partial agonists of the a2a adenosine receptor |
US20050020915A1 (en) * | 2002-07-29 | 2005-01-27 | Cv Therapeutics, Inc. | Myocardial perfusion imaging methods and compositions |
CA2492855C (en) * | 2002-07-29 | 2012-09-18 | Cv Therapeutics, Inc. | Myocardial perfusion imaging using a2a receptor agonists |
US8470801B2 (en) | 2002-07-29 | 2013-06-25 | Gilead Sciences, Inc. | Myocardial perfusion imaging methods and compositions |
EP1572678A4 (en) * | 2002-12-19 | 2008-05-07 | Elan Pharm Inc | SUBSTITUTED N-PHENYL SULPHONAMIDES ALSBRADYKININ ANTAGONISTS |
EP1802317A2 (en) | 2004-10-20 | 2007-07-04 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists |
GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
AU2007212542B2 (en) | 2006-02-03 | 2013-01-31 | Gilead Sciences, Inc. | Process for preparing an A2A-Adenosine receptor agonist and its polymorphs |
EP2068850A1 (en) * | 2006-06-22 | 2009-06-17 | Cv Therapeutics, Inc. | Use of a2a adenosine receptor agonists in the treatment of ischemia |
MX2009002299A (es) * | 2006-09-01 | 2009-03-20 | Cv Therapeutics Inc | Metodos y composiciones para incrementar la tolerancia del paciente durante metodos de formacion de imagenes del miocardio. |
US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
EP2066232A1 (en) * | 2006-09-29 | 2009-06-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
WO2008086096A2 (en) * | 2007-01-03 | 2008-07-17 | Cv Therapeutics, Inc. | Myocardial perfusion imaging |
WO2009118292A1 (en) * | 2008-03-24 | 2009-10-01 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
US20100086483A1 (en) * | 2008-09-29 | 2010-04-08 | Gilead Palo Alto, Inc. | Method of multidetector computed tomagraphy |
EP2316820A1 (en) | 2009-10-28 | 2011-05-04 | Dompe S.p.A. | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them |
US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
JP2015525202A (ja) | 2012-05-03 | 2015-09-03 | ノバルティス アーゲー | グレリン受容体アゴニストとしての2,7−ジアザ−スピロ[4,5]デカ−7−イル誘導体のl−リンゴ酸塩およびその結晶形態 |
HUE032179T2 (hu) * | 2013-06-14 | 2017-09-28 | Dompe Farm Spa | Bradikinin receptor antagonisták és az ezeket tartalmazó gyógyászati készítmények |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE120047C (es) * | ||||
FR2743562B1 (fr) * | 1996-01-11 | 1998-04-03 | Sanofi Sa | Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant |
CA2372715A1 (en) * | 1999-05-13 | 2001-04-12 | Shionogi & Co., Ltd. | Preventive or therapeutic drugs for diabetes |
GB9913079D0 (en) * | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
-
2002
- 2002-05-13 CN CNB028098900A patent/CN1268610C/zh not_active Expired - Fee Related
- 2002-05-13 EP EP02742997A patent/EP1389183B1/en not_active Expired - Lifetime
- 2002-05-13 AR ARP020101737A patent/AR035891A1/es unknown
- 2002-05-13 PT PT02742997T patent/PT1389183E/pt unknown
- 2002-05-13 ES ES02742997T patent/ES2340664T3/es not_active Expired - Lifetime
- 2002-05-13 DE DE60235536T patent/DE60235536D1/de not_active Expired - Fee Related
- 2002-05-13 BR BR0209386-3A patent/BR0209386A/pt not_active IP Right Cessation
- 2002-05-13 JP JP2002589442A patent/JP4150597B2/ja not_active Expired - Fee Related
- 2002-05-13 US US10/475,420 patent/US7109203B2/en not_active Expired - Fee Related
- 2002-05-13 CA CA002443721A patent/CA2443721A1/en not_active Abandoned
- 2002-05-13 WO PCT/EP2002/005240 patent/WO2002092556A1/en active Application Filing
- 2002-05-13 AT AT02742997T patent/ATE459598T1/de not_active IP Right Cessation
- 2002-05-14 PE PE2002000401A patent/PE20021158A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20040127533A1 (en) | 2004-07-01 |
CN1268610C (zh) | 2006-08-09 |
EP1389183B1 (en) | 2010-03-03 |
DE60235536D1 (de) | 2010-04-15 |
AR035891A1 (es) | 2004-07-21 |
JP4150597B2 (ja) | 2008-09-17 |
BR0209386A (pt) | 2004-07-06 |
EP1389183A1 (en) | 2004-02-18 |
WO2002092556A1 (en) | 2002-11-21 |
US7109203B2 (en) | 2006-09-19 |
JP2004528385A (ja) | 2004-09-16 |
CN1509269A (zh) | 2004-06-30 |
CA2443721A1 (en) | 2002-11-21 |
ATE459598T1 (de) | 2010-03-15 |
PT1389183E (pt) | 2010-04-26 |
ES2340664T3 (es) | 2010-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20021158A1 (es) | Derivados de sulfonamida como antagonistas del receptor de bradiquinina | |
PE20020506A1 (es) | Derivados de pirazol fusionados como inhibidores de la proteina cinasa | |
PE20030702A1 (es) | Inhibidores de pde9 para tratamiento de transtornos cardiovasculares | |
PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
CO5690643A2 (es) | Derivados de triaza-espiropiperidina para usarlos como inhibidores de glyt-1 en el tratamiento de desordenes neurologicos y neuropsiquiatricos | |
PE20060693A1 (es) | Nuevos derivados de trifluorometansulfonanilida oxamida eter | |
MEP61208A (en) | Novel compounds having inhibitory activity against sodium-dependant transporter | |
HUP0402236A2 (hu) | Heterociklusos vegyületek, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
EA200700047A1 (ru) | Новые алкильные производные в качестве метаботропных рецепторов глутамата | |
PE20021094A1 (es) | Derivados de ciclohexano-1,4-diamina sustituidos | |
PE20051146A1 (es) | Compuestos heterociclicos anticitocina | |
PE20081263A1 (es) | DERIVADOS DE 4-(2-AMINO-1-HIDROXIETIL)FENOL COMO AGONISTAS DEL RECEPTOR ß2 ADRENERGICO | |
PE20020917A1 (es) | Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato | |
PE20040987A1 (es) | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf) | |
PE20040988A1 (es) | Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf) | |
PE20060727A1 (es) | Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf) | |
AR062299A1 (es) | Derivados de bencimidazol | |
RU2005135338A (ru) | Замещенные 3-цианотиофенацетамиды в качестве антагонистов рецептора глюкагона | |
PE20020258A1 (es) | Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina 1 (nk-1) | |
MX2009013119A (es) | Derivados de 2-[2-(fenil)etilamino]alcanamida sustituidos y su uso como moduladores del canal de sodio y/o potasio. | |
PE75199A1 (es) | Derivado de quinolina util como antagonista de neuroquinina | |
PE20030541A1 (es) | Compuestos pirimidina de anillo fusionado alquinilado como inhibidores de metaloproteasa de matriz tipo 13 | |
BG94282A (bg) | 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они | |
NZ528997A (en) | Sulfonamides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |